LUCA Biologics Launches to Develop Live Biotherapeutics for Women's Health Starting with Urinary Tract Infection (UTI)
Emerging from 15 years of Dr. Jacques Ravel's vaginal microbiome research,LUCA's pipeline targets UTI, bacterial vaginosis (BV), and preterm birth (PTB)
LUCA Biologics, a biotechnology company co-founded by Dr. Jacques Ravel, announced today it will develop live biotherapeutics for widespread, unmet medical needs in women's health. Ravel will serve as LUCA's Chief Scientist.
The company's first therapeutic targets urinary tract infection (UTI), estimated by the Worl...